Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.40 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23751272 | 1.00 | ALOX5 (0.46) | ALOX5PKMMAPTMEN1ALDH1A1 | |
| SCHEMBL23751269 | 1.00 | ALOX5 (0.46) | ALOX5PKMMAPTMEN1ALDH1A1 | |
| SCHEMBL31721993 | 1.00 | ALOX5 (0.46) | ALOX5PKMMAPTMEN1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL28905944 | 0.98 | ALOX5 (0.45) | ALOX5PKMMAPTMEN1ALDH1A1 | |
| SCHEMBL16245939 | 0.82 | SLC7A5 (0.42) | PKMMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL7032384 | 0.80 | PKM (0.53) | ALOX5PKMMAPTMEN1ALDH1A1 | |
| SCHEMBL27783140 | 0.79 | PKM (0.46) | PKMMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL2025468 | 0.79 | PKM (0.51) | ALOX5PKMMAPTMEN1ALDH1A1 | |
| Biphenyl SCHEMBL28253359 | 0.79 | CYP17A1 (0.37) | ALOX5APPCNR2KDM4E | |
| SCHEMBL5164703 | 0.77 | HDAC3 (0.46) | ALOX5PKMMAPTMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 634 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339569-A1 | CARBONIC ANHYDRASE IX LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2025-11-06 | — | — | US | claimed |
| US-20250250298-A1 | ONCOLYTIC PEPTIDE AND USE THEREOF | RISE BIOPHARMACEUTICALS INC. (CN) | 2025-08-07 | — | — | US | claimed |
| WO-2025073102-A1 | ONCOLYTIC PEPTIDE AND USE THEREOF FOR INHIBITING CANCER CELL VIABILITY | LT BIOPHARMA INC. (CN) | 2025-04-10 | — | — | WO | claimed |
| CN-119213011-A | Radiolabeled compounds for in vivo imaging of the Gastrin Releasing Peptide Receptor (GRPR) and treatment of GRPR-related disorders | 省卫生服务机构 | 2024-12-27 | — | — | CN | claimed |
| EP-4448544-A2 | CARBONIC ANHYDRASE IX LIGANDS | 3B Pharmaceuticals GmbH (DE) | 2024-10-23 | — | — | EP | claimed |
| CN-118359680-A | Semglutide derived stapling peptide and preparation method and application thereof | 西安交通大学 | 2024-07-19 | — | — | CN | claimed |
| CN-117915957-A | Compositions and methods for modulating mRNA splicing | 恩特拉达治疗学股份有限公司 | 2024-04-19 | — | — | CN | claimed |
| CN-117561271-A | Cyclic cell penetrating peptides | 恩特拉达治疗公司 | 2024-02-13 | — | — | CN | claimed |
| EP-4294820-A1 | CYCLIC CELL-PENETRATING PEPTIDES WITH THREE OR MORE HYDROPHOBIC RESIDUES | Ohio State Innovation Foundation (US) | 2023-12-27 | — | — | EP | claimed |
| WO-2023197129-A1 | ONCOLYTIC PEPTIDE AND USE THEREOF | RISE BIOPHARMACEUTICALS INC. (CN) | 2023-10-19 | — | — | WO | claimed |
| US-20030166567-A1 | Anti-aging and wound healing compounds | KIMBERLY-CLARK WORLDWIDE, INC. | 2003-09-04 | — | — | US | claimed |
| US-20030148959-A1 | Anti-aging and wound healing compounds | AVANOS MEDICAL SALES, LLC | 2003-08-07 | — | — | US | claimed |
| WO-2003057820-A2 | PEPTIDE ACTIVATORS OF VEGF | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2003-07-17 | — | — | WO | claimed |
| US-20030114362-A1 | Penta-or tetrapeptide binding to somatostatin receptors and the use of the same | NOVASPIN BIOTECH GMBH (DE) | 2003-06-19 | — | — | US | claimed |
| US-20030096757-A1 | Anti-cancer and wound healing compounds | KIMBERLY-CLARK WORLDWIDE, INC. | 2003-05-22 | — | — | US | claimed |
| WO-2003033528-A1 | CYCLIC PEPTIDES AS G-PROTEIN-COUPLED RECEPTOR ANTAGONISTS | UNIVERSITY OF QUEENSLAND (AU) | 2003-04-24 | — | — | WO | claimed |
| WO-2003018748-A2 | ANTI-CANCER AND WOUND HEALING COMPOUNDS | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2003-03-06 | — | — | WO | claimed |
| WO-2003016520-A1 | ANTI-AGING AND WOUND HEALING COMPOUNDS | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2003-02-27 | — | — | WO | claimed |
| WO-2002100885-A2 | A PENTA- OR TETRAPEPTIDE BINDING TO SOMATOSTATIN RECEPTORS AND THE USE OF THE SAME | NOVASPIN BIOTECH GMBH (DE) | 2002-12-19 | — | — | WO | claimed |
| CN-1234735-A | Method for treating skin pigmentation | JOHNSON & JOHNSON CONSUMER (US) | 1999-11-10 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339569-A1 | CARBONIC ANHYDRASE IX LIGANDS | CA9, CA13, CA4 | ALOX5 3721/4885PKM 2993/4885MAPT 2838/4885 |
| US-20030114362-A1 | Penta-or tetrapeptide binding to somatostatin receptors and the use of the same | SSTR5, SSTR3, SCTR | ALOX5 329/4885PKM 2886/4885MAPT 2988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.